Inhibikase reports Q2 2026 results as Phase 3 PAH trial expands across 26 countries
The company said its IMPROVE-PAH study has cleared regulatory review in 26 countries and started dosing at 43 sites, while cash and the July $50 million raise are meant to fund the trial through Part B data.
SEC filing